AstraZeneca invests $2.5 billion in Beijing hub amid probe
AstraZeneca Plc will invest $2.5 billion in a new research center in Beijing, in a major show of commitment to China just months after the company’s top executive there was detained by authorities. Most Read from BloombergNew York Subway Ditches MetroCard After 32 Years for Tap-And-GoDespite Cost-Cutting Moves,
Tallying up a wide range of investments, AstraZeneca said it is pumping $2.5 billion into Beijing. The figure includes ...
AstraZeneca announced on Friday an investment of $2.5 billion in Beijing to establish the pharmaceutical company's sixth ...
AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...
The deal includes the Belgian biotech’s in-vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...
AstraZeneca scrapped a £450m vaccine plant in Liverpool after the UK government missed a critical funding deadline. The ...
AstraZeneca is hopping on the pickleball craze for the latest iteration of its Stepping Back Out campaign for asthma treatment Fasenra.
Clinical Trials Arena on MSN3d
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase IIIAstraZeneca acquired the hypoparathyroidism therapy eneboparatide as part of a buyout of Amolyt Pharma in July 2024.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback